Romidepsin Plus ICE, Clinical Trials, T-Cell Lymphoma

Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

This study is ongoing, but no longer recruiting participants.

The goal of this clinical research study is find the highest tolerable dose of romidepsin that can be given in combination with ifosfamide, carboplatin, etoposide (ICE) to patients with PTCL. The safety of this drug combination will also be studied.        

Romidepsin is designed to stop the growth of cancer cells and block new blood vessels from forming around the cancer cells. This may cause the cancer cells to die.                                 
Ifosfamide and etoposide are designed to slow or stop the growth of cancer cells.                          

Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may cause the cells to die.

Study Type:    Interventional

Study Design:    

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment


Official Title:    Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Condition:  Lymphoma                    

Interventions:  

Drug: Romidepsin
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin
Drug: Etoposide                          

Phase:  Phase 1

External Links:  https://clinicaltrials.gov/show/NCT01590732